Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2019–2024

MIRIADE · Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2019-11-01 → 2024-08-31
Финансиране от ЕС
4 034 545 €
Участници
11
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Биомаркери в телесните течности помагат за по-точно диагностициране на различните видове деменция. Те са необходими, за да се разбере по-добре заболяването и да се ускори разработването на ефективни лекарства.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis

Dementia is a threatening disease due to its increasing incidence in the aging population, bulging costs and inhumane clinical course, while no cure is currently available. To make progress in the development of effective drugs for dementia, there is an urgent need for body fluid biomarkers to enable precision health for different forms of dementia. The aim of MIRIADE was to train a new generation of scientists able to optimise and accelerate development of novel body fluid biomarkers for dementia. MIRIADE had the following aims: o To equip 15 scientists with unique skills and strategies to target biomarker development (WP6). o To establish a roadmap for strong stakeholder interactions to accelerate the biomarker development process (WP1-5,7). o To develop an open integrated data platform for biomarker development (WP1). o To develop computational tools for rational prediction of biomarkers (WP1,2). o To develop and validate novel biomarker assays for specific types of dementia (WP1-3). o To facilitate clinical implementation of biomarker assays (WP4). Conclusions: MIRIADE trained 15 specialised ESRs to optimise and accelerate development of novel dementia biomarkers through dedicated training programs, research activities and intersectoral collaboration (including secondments). In WP1, existing -omics data were integrated to identify candidate biomarkers, which has led as to the creation of an open database and a dementia disease map. WP2 concentrated on generating assays for several biomarkers, employing various technologies in parallel. This led to the successful generation of several novel robust assays. WP3 clinically validated the developed biomarkers, achieving positive results for several assays. WP4 further advanced these assays for market readiness, focusing on preanalytical stability and developing standard operating procedures (SOPs) for clinical use. WP5 analyzed workflows and collaboration across research groups, identifying bottlenecks and opportunities to improve biomarker development, with a focus on inter-group collaboration and data sharing and reuse practices.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Dementia is currently diagnosed largely based on cognitive decline, while pathology starts years before symptom onset. To make progress in the development of effective drugs for dementia, there is an urgent need for biomarkers to enable precision health: for early and specific diagnosis and objective monitoring of disease progression. With its multidisciplinary team of scientists from academia, industry, and patient organisations, MIRIADE aims to train a new generation of scientists able to optimise and accelerate development of novel biomarkers for dementia. MIRIADE will integrate biomarker discovery data from multiple platforms and develop a Dementia Disease Map to enhance biomarker identification (WP1). We will develop assays for prioritized biomarkers (WP2), and selected markers will be clinically validated (WP3). We will study pre-analytical stability and validate against regulatory requirements (WP4) and develop a roadmap for optimal biomarker development (WP5). MIRIADE will thus establish an innovative biomarker-focussed cross-sectoral research and training programme that will equip ESRs with a unique combination of skills in big data analysis, biomarker assay development, innovation management, and a thorough understanding of medical needs. This programme will provide a new task force of scientists that are optimally trained to the accelerate the biomarker development for dementias and able to progress effective biomarker tools to the clinic.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз